Form 4: Corbus Pharmaceuticals CEO Yuval Cohen Executes Stock Options and Sells Shares Under 10b5-1 Plan

Corbus Pharmaceuticals' CEO, Yuval Cohen, exercised stock options and sold shares between June 14 and June 18, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Yuval Cohen, CEO of Corbus Pharmaceuticals Holdings, Inc., filed a Form 4 detailing changes in beneficial ownership.
• Between June 14 and June 18, 2024, Cohen exercised options to purchase common stock and sold shares.
• The transactions were executed under a Rule 10b5-1 trading plan adopted on March 15, 2024.
• The exercise prices for the options ranged from $4.26 to $30.
• The sale prices for the common stock ranged from $40.75 to $52.23 per share.
• Following these transactions, Cohen directly owns 77,221 shares of common stock and holds options to purchase additional shares.
• The reported amount includes 73,947 restricted stock units (RSUs) which vest beginning on February 12, 2025.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transactions were pre-planned under a 10b5-1 trading plan and do not necessarily reflect a change in the executive's outlook on the company.

Industry Context

Executive stock transactions are common and closely watched, as they can provide insights into management's perspective on the company's value and future prospects. A 10b5-1 plan allows insiders to sell shares over a period of time, mitigating concerns about insider trading.

Stakeholder Impact

• Shareholders may interpret the CEO's stock sales in various ways, although the existence of a 10b5-1 plan suggests the transactions were pre-planned.
• Employees may be interested in executive stock transactions as an indicator of company performance and management confidence.

Key Dates